Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma: Evaluation of clinical benefit, quality of life, and tolerance

Cancer

Volumn 98, Issue 8, 2003, Pages 1627-1634

  Gravis, Gwenaelle ^a   Bladou, Franck ^b,c,d   Salem, Naji ^a   Macquart Moulin, Geneviève ^a   Serment, Gérard ^b,d   Camerlo, Jacques ^a   Genre, Dominique ^a   Bardou, Valérie Jeanne ^a   Maraninchi, Dominique ^a,d   Viens, Patrice ^a,c,d  

^a INSTITUT PAOLI CALMETTES   (France)

^b Child and Adolescent Psychopathology Unit Salvator Hospital Public Assistance Marseille Hospitals University Aix Marseille II   (France)

^c INSERM   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Docetaxel; Hormone refractory prostate carcinoma; Taxanes; Weekly

Indexed keywords

ANTIANDROGEN; DOCETAXEL; ESTRAMUSTINE; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TAXANE DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DERMATITIS; DIARRHEA; DOSE RESPONSE; DRUG TOLERABILITY; EDEMA; FATIGUE; HORMONAL THERAPY; HORMONE REFRACTORY PROSTATE CARCINOMA; HUMAN; LIVER TOXICITY; LYMPH NODE METASTASIS; MALE; MUCOSA INFLAMMATION; MYALGIA; NEUROTOXICITY; NEUTROPENIA; ONYCHOLYSIS; PELVIS LYMPH NODE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; QUALITY OF LIFE; RISK BENEFIT ANALYSIS;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TAXOIDS;

EID: 0141923869     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11687     Document Type: Article

References (22)

1. American Cancer Society. Selected cancers: prostate. In: Cancer facts and figures 2001. Atlanta: American Cancer Society, 2001:16-17.
2. Crawford E, Eisenberger M, McLeod D, et al. A controlled trial of leuprolide with and without flutamide in prostate carcinoma. N Engl J Med. 1989;17:419-424.
3. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 1993;71:1098-1109.
4. Kantoff P, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol. 1999;17:2506-2513.
5. Tannock I, Osoba D, Stockler M, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756-1764.
6. Friedland D, Cohen J, Miller J, et al. A Phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol. 1999;26:19-23.
7. Petrylak D, Macarthur R, O'Connor J, et al. Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer. Semin Oncol. 1999;26:28-33.
8. Picus J, Schultz M. A Phase II trial of docetaxel in patients with hormone refractory prostate cancer (HRPC): long term results [abstract]. Proc Am Soc Clin Oncol. 1999;18: 1206.
9. Fennely D, Aghajanian C, Shapiro F, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol. 1997;15: 187-192.
10. Hainsworth J, Burris H, Erland J, Thomas M, Greco F. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol. 1998; 16:2164-2168.
11. Burris H, Moore M, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
12. Fields-Jones S, Koletsky A, Wilding G, et al. Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a Phase II trial. Ann Oncol. 1999;10:1307-1310.
13. Huskisson E. Measurement of pain. Lancet. 1974;2:1127-1131.
14. Aaronson N, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376.
15. Fayers P, Aaronson N, Bjordal K, Curran D, Groenvold M. The EORTC QLQ-C30 scoring manual. Brussels: European Organization for Research and Treatment of Cancer, 1999.
16. da Silva F, Fossa S, Aaronson N, et al. The quality of life of patients with newly diagnosed M1 prostate cancer: experience with EORTC clinical trial 30853. Eur J Cancer. 1996;32:72-77.
17. Kelly W, Scher H, Mazumdar M, Vlamis M, Schwartz M, Fossa S. Prostate specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol. 1993;11:607-615.
18. Fleming T. One sample multiple testing procedure for Phase II clinical trials. Biometrics. 1982;38:143-151.
19. Fossa SA, Newling D, van Cangh P, et al. Quality of life and treatment of hormone resistant metastatic prostate cancer. The EORTC Genito-Urinary Group. Eur J Cancer. 1990;26: 1133-1136.
20. Bubley G, Carducci M, Dahut W, et al. Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461-3467.
21. Beer T, Pierce W, Lowe B, Henner W. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol. 2001;12:1273-1279.
22. Oudard S, Banu E, Vannetzel L, et al. Results of a Phase II randomized trial of docetaxel, estramustine and prednisone-two schedules-versus mitoxantrone and prednisone in patients with hormone refractory prostate cancer (HRPC) [abstract]. Ann Oncol. 2002;13:90.